| Target Price | HK$6.43 |
| Price | HK$4.38 |
| Potential |
46.71%
register free of charge
|
| Number of Estimates | 11 |
|
11 Analysts have issued a price target China Resources Pharmaceutic 2027 .
The average China Resources Pharmaceutic target price is HK$6.43.
This is
46.71%
register free of charge
HK$7.90
80.27%
register free of charge
HK$5.70
30.05%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend China Resources Pharmaceutic to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the China Resources Pharmaceutic stock has an average upside potential 2027 of
46.71%
register free of charge
|
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion HK$ | 315.67 | 324.27 |
| 4.62% | 2.72% | |
| EBITDA Margin | 6.64% | 6.32% |
| 4.54% | 4.83% | |
| Net Margin | 1.50% | 1.49% |
| 15.40% | 0.71% |
11 Analysts have issued a sales forecast China Resources Pharmaceutic 2026 . The average China Resources Pharmaceutic sales estimate is
This results in the following potential growth metrics:
10 China Resources Pharmaceutic Analysts have issued a net profit forecast 2026. The average China Resources Pharmaceutic net profit estimate is
This results in the following potential growth metrics and future Net Margins:
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share HK$ | 0.75 | 0.77 |
| 20.97% | 2.67% | |
| P/E | 5.64 | |
| EV/Sales | 0.22 |
10 Analysts have issued a China Resources Pharmaceutic forecast for earnings per share. The average China Resources Pharmaceutic EPS is
This results in the following potential growth metrics and future valuations:
China Resources Pharmaceutic...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


